PP
AERI

Paloma Partners’s Aerie Pharmaceuticals AERI Stock Holding History

Paloma Partners’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-27,844
Closed -$328K – 2395
2020
Q3 		$328K Sell
27,844
-715
-3% -$8.71K 0.01% 1429
2020
Q2 		$422K Buy
+28,559
New +$422K 0.01% 1308
2017
Q4 		– Sell
-5,573
Closed -$271K – 2408
2017
Q3 		$271K Buy
+5,573
New +$304K ﹤0.01% 1844

Other funds holding AERI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Paloma Partners's AERI Position: Q4 2020 in Review

Paloma Partners sold out of Aerie Pharmaceuticals (AERI) in Q4 2020, closing a stake of 27,844 shares — an estimated $328K sold.

Paloma Partners first reported a position in AERI in Q3 2017 and held it in 3 quarters. The position peaked at $422K in Q2 2020. 150 funds tracked by Wall St. Rank hold AERI as of Q4 2020.

  • Paloma Partners reported no remaining Aerie Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Paloma Partners sold 27,844 Aerie Pharmaceuticals shares in Q4 2020, an estimated $328K.
  • Paloma Partners first reported a position in Aerie Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • Paloma Partners's Aerie Pharmaceuticals position peaked at $422K in Q2 2020.
  • 150 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2020.

Based on Paloma Partners's 13F filing for Q4 2020, filed 16 Feb 2021.